Drug Shortage Report for TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR
Report ID | 112370 |
Drug Identification Number | 02393549 |
Brand name | TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR |
Common or Proper name | EFAVIR/EMTRICIT/TENOF 600/200/300MG |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | EFAVIRENZ EMTRICITABINE TENOFOVIR DISOPROXIL FUMARATE |
Strength(s) | 600MG 200MG 300MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 30 |
ATC code | J05AR |
ATC description | DIRECT ACTING ANTIVIRALS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2020-04-15 |
Estimated end date | 2020-05-31 |
Actual end date | 2020-05-07 |
Shortage status | Resolved |
Updated date | 2020-05-08 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2020-05-08 | French | Compare |
v3 | 2020-05-08 | English | Compare |
v2 | 2020-04-16 | French | Compare |
v1 | 2020-04-16 | English | Compare |
Showing 1 to 4 of 4